OP-1118 (Fidaxomicin metabolite OP-1118) is an orally effective dual inhibitor of NF-kappaB and ERK1/2, with low systemic plasma exposure, no accumulation, and primary excretion via feces. By inhibiting the phosphorylation of NF-kappaB and ERK1/2 and reducing the expression of pro-inflammatory cytokines, OP-1118 exerts significant anti-inflammatory, cytoprotective, anti-apoptotic and antibacterial activities. In Clostridium difficile infection models, OP-1118 effectively blocks toxin-mediated intestinal inflammation, cell rounding, histological damage and apoptosis, and its protective effect can be reversed by PMA (HY-18739)[1][2][3].
Molecular Weight:
987.95
CAS Number:
[1030825-28-5]
Formula:
C48H68Cl2O17
Target:
Apoptosis,Bacterial,ERK,NF-kappaB
Application Notes:
MCE Product type: Reference compound
* VAT and and shipping costs not included. Errors and price changes excepted
